{
    "clinical_study": {
        "@rank": "161349", 
        "arm_group": {
            "arm_group_label": "FSH", 
            "arm_group_type": "Experimental", 
            "description": "FSH (Follicle stimulation hormone, 75 IU/vial) will be administered to women according to their need and response assessed by the Investigator."
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate immunogenic potential of FSH-IBSA in healthy\n      volunteers undergoing controlled ovarain hyperstimulation (COH) in an oocyte donation\n      program."
        }, 
        "brief_title": "Immunogenicity of Repeated Follicle Stimulating Hormone (FSH) Stimulation Cycles", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Infertility; Oocytes Donation; Immunogenicity.", 
        "condition_browse": {
            "mesh_term": "Infertility"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy female volunteers undergoing controlled ovarian hyperstimulation for oocyte\n             donation with the following characteristics:\n\n          -  Able and willing to sign the Subject Consent Form and adhere to the study visit\n             schedule;\n\n          -  >=18 and <35 years old;\n\n          -  Regular menstrual cycle (26 - 35 days);\n\n          -  BMI between 18 and 30 kg/m2;\n\n          -  First gonadotrophin treatment (i.e. na\u00efve Subjects with regard to exposure to human\n             derived or recombinant gonadotrophins);\n\n          -  basal FSH <10 IU/L and E2 <80 pg/ml (~290 pmol/l);\n\n          -  Normal TSH levels;\n\n          -  Willing to perform at least two consecutive oocyte retrieval cycles (with a wash out\n             period of two months).\n\n        Exclusion Criteria:\n\n          -  Age <18 and >=35 years;\n\n          -  PCOS;\n\n          -  Endometriosis;\n\n          -  Subjects with evidences of autoimmune or rheumatic diseases;\n\n          -  Hypersensitivity to the active substance or to any of the excipients (lactose);\n\n          -  Abnormal bleeding of undetermined origin;\n\n          -  Subject found to be positive to anti-TSH antibodies (i.e. suffering from thyroidal\n             diseases);\n\n          -  Uncontrolled adrenal dysfunction;\n\n          -  Neoplasia;\n\n          -  Severe impairment of renal and/or hepatic function;\n\n          -  Use of concomitant medications that might interfere with study evaluations (e.g.\n             immunosuppressant, non-study hormonal medications, therapeutics proteins like\n             insulin, growth hormone\u2026)."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "35 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01785095", 
            "org_study_id": "11E/FSH03"
        }, 
        "intervention": {
            "arm_group_label": "FSH", 
            "intervention_name": "FSH (Follicle Stimulating Hormone)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Hormones", 
                "Follicle Stimulating Hormone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 4, 2013", 
        "location": {
            "contact": {
                "last_name": "Buenaventura Coroleu Lletget, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Barcelona", 
                    "country": "Spain", 
                    "zip": "8028"
                }, 
                "name": "Dep.Obstet-Gynec.-Reproduction,Institut Universitari Dexeus"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "1", 
        "official_title": "Prospective, Open-label, Uncontrolled Clinical Trial Evaluating Multiple Controlled Ovarian Hyperstimulation Cycles in Oocyte Donor, to Assess the Immunogenicity of FSH-IBSA", 
        "overall_contact": {
            "email": "vencor@dexeus.com", 
            "last_name": "Buenaventura Coroleu Lletget, MD"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The immunogenicity potential of FSH in healthy volunteer will be assessed by analysing serum samples collected at different timepoints during two treatment cycle for oocytes donation: cycle 1, serum samples will be collected before treatment start (baseline), after 7-13 days and after 28 days of treatment; Cycle 2: serum samples will be collected before starting the second cycle (baseline 2), after 7-13 days and after 28 days of treatment. Cycle 1 and cycle 2 will be separated by a wash-out period of two months.", 
            "measure": "Production of anti-FSH antibodies.", 
            "safety_issue": "Yes", 
            "time_frame": "4 months."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01785095"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Adverse events occuring during the study period will be collected.", 
            "measure": "Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "4 months."
        }, 
        "source": "IBSA Institut Biochimique SA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "IBSA Institut Biochimique SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2013"
    }
}